NasdaqGM - Nasdaq Real Time Price USD

Arcturus Therapeutics Holdings Inc. (ARCT)

Compare
18.00 +0.27 (+1.52%)
At close: 4:00 PM EDT
18.01 +0.01 (+0.06%)
After hours: 4:50 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Joseph E. Payne M.Sc. Founder, President, CEO & Director 906.5k -- 1972
Dr. Padmanabh Chivukula Ph.D. Founder, Chief Scientific Officer, COO & Secretary 687.5k -- 1979
Mr. Andrew H. Sassine MBA CFO & Director 687.5k -- 1964
Mr. Lance Kurata Chief Legal Officer 600k -- --
Ms. Neda Safarzadeh Vice President and Head of IR/PR & Marketing -- -- --
Ms. Natash O. Bowman Chief Human Resources Officer -- -- --
Mr. Kevin T. Skol Chief Business Officer -- -- --
Dr. Juergen Froehlich FCPh, M.D., MBA Chief Medical Officer -- -- 1956
Dr. Igor Smolenov M.D., Ph.D. Chief Development Officer -- -- --
Ms. Roberta Duncan Chief Strategy Officer -- -- --

Arcturus Therapeutics Holdings Inc.

10628 Science Center Drive
Suite 250
San Diego, CA 92121
United States
858 900 2660 https://arcturusrx.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
180

Description

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Corporate Governance

Arcturus Therapeutics Holdings Inc.’s ISS Governance QualityScore as of November 1, 2024 is 7. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 6; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 12, 2024 at 9:00 PM UTC - November 18, 2024 at 9:00 PM UTC

Arcturus Therapeutics Holdings Inc. Earnings Date

Recent Events

September 18, 2024 at 12:00 PM UTC

at Cantor Global Healthcare Conference

September 9, 2024 at 3:00 PM UTC

at HC Wainwright Global Investment Conference

September 4, 2024 at 7:00 PM UTC

at Wells Fargo Healthcare Conference

August 13, 2024 at 1:30 PM UTC

at Canaccord Genuity Growth Conference

August 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 5, 2024 at 8:30 PM UTC

Q2 2024 Earnings Call

August 5, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 17, 2024 at 12:00 AM UTC

S-8: Offering Registrations

June 24, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 14, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers